Início › Doenças Autoimunes › Massachusetts › Boston
Ensaios clínicos de Doenças Autoimunes em Boston, MA
13 estudos para Doenças Autoimunes estão buscando participantes em locais em Boston e arredores (num raio de aproximadamente 30 milhas). Abra um estudo para ver quem pode participar e como contatar a equipe.
Texto oficial do estudo (Inglês)
Recrutando participantes para um estudo? Destaque-o no topo desta página — $99 por 30 dias →
Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
RecrutandoFase 3
- Tufts Medical Center, Boston
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
RecrutandoFase 1
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
RecrutandoFase 3
- Massachusetts General Hospital, Boston
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
RecrutandoFase 2/3
- Boston Children's Hospital - Accepting Young Adults and Juvenile Patients, Boston
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
RecrutandoFase 3
- Massachusetts General Hospital, Boston
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
RecrutandoFase 1/2
- Tufts Medical Center, Boston
- Massachusetts General Hospital, Boston
- Boston Children's Hospital, Boston
- e mais 1
RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
RecrutandoFase 1/2
- Beth Israel Deaconess Medical Center, Boston
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
RecrutandoFase 3
- Boston Children's Cancer Center, Boston
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
RecrutandoFase 1
- Brigham And Womens Hospital, Boston
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RecrutandoEstudo observacional
- Tufts Medical Center, Boston
- Beth Israel Deaconess, Boston
- Dana Farber Cancer Institute, Boston
Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis
RecrutandoFase 1
- Tufts University, Boston
- Massachusetts General Hospital, Boston
- Brigham and Women's Hospital, Boston
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
RecrutandoFase 1/2
- Brigham and Women's Hospital, Boston
Testimonials and Navigation in Rheumatology
Recrutando
- Brigham Women's Hospital, Boston
Ensaios de Doenças Autoimunes em outras cidades
- Houston, TX21 estudos
- Washington, DC19 estudos
- New York City, NY19 estudos
- Philadelphia, PA16 estudos
- Durham, NC15 estudos
- Los Angeles, CA12 estudos
- Chicago, IL12 estudos
- Dallas, TX9 estudos
- Cleveland, OH8 estudos
- Milwaukee, WI8 estudos
- Atlanta, GA8 estudos
- Portland, OR8 estudos
Outros estudos em Boston
- Câncer de Mama111 estudos
- Câncer de Pulmão de Não Pequenas Células90 estudos
- Câncer (todos os tipos)86 estudos
- Câncer Colorretal63 estudos
- Câncer Metastático63 estudos
- Câncer de Pulmão62 estudos
- Câncer de Ovário61 estudos
- Câncer de Próstata59 estudos
- Depressão52 estudos
- Câncer Endometrial50 estudos
- Insuficiência Cardíaca44 estudos
- Leucemia Mieloide Aguda44 estudos
Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.